Article Details

EyePoint sees stock surge on AMD drug trial data | BioPharma Dive

Retrieved on: 2023-12-04 16:48:07

Tags for this article:

Click the tags to see associated articles and topics

EyePoint sees stock surge on AMD drug trial data | BioPharma Dive. View article details on hiswai:

Excerpt

The biotech said Phase 2 study results showed its experimental medicine for age-related macular degeneration was “non-inferior” to Regeneron's Eylea.

Article found on: www.biopharmadive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up